Anika Therapeutics, a provider of products for tissue protection, healing and repair based on hyaluronic acid technology, has signed an exclusive agreement with DePuy Mitek, a Johnson & Johnson company, to distribute and market Orthovisc and Orthovisc mini throughout Latin America.
This five-year renewable agreement gives DePuy Mitek exclusive distribution rights for both products in all of South America, Central America, the Caribbean and Mexico. DePuy Mitek currently distributes Orthovisc in the US.
Orthovisc is indicated in the US for the treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and to simple analgesics, such as acetaminophen.
Charles Sherwood, president and CEO of Anika, said: “This agreement with DePuy Mitek to distribute Orthovisc, our flagship osteoarthritis product, as well as Orthovisc mini for the treatment of smaller joints, throughout Latin America gives us a strong foothold in a new and exciting market. Industry analysts have projected the osteoarthritis market in Latin America to grow at a rate of nearly 20% per year through 2016.”